Astria Therapeutics (ATXS) AI Stock Analysis

• Market Cap: $718.13M
• Dividend Yield: N/A
• Average Volume (3M): 871.52K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.73
• Revenue Growth: N/A
• EPS Growth: -2.74%
• Country: US
• Employees: 78
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.55
• Shares Outstanding: 57,084,840
• 10 Day Avg. Volume: 1,039,098
• 30 Day Avg. Volume: 871,525
• PEG Ratio: 0.17
• Price to Book (P/B): 1.57
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -6.16
• Enterprise Value/Market Cap: 0.87
• Enterprise Value/Revenue: 887.12
• Enterprise Value/Gross Profit: 887.12
• Enterprise Value/Ebitda: -4.67
• 1Y Price Target: $13.00
• Price Target Upside: 3.34% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 51 Neutral
• Price Target: $12.50 ▼(-0.64% Downside)

The score is held down primarily by weak financial performance—minimal revenue, large losses, and rising cash burn—despite low leverage. Technicals are mixed with softer near-term momentum but a still-positive longer-term trend, while valuation support is limited by the negative P/E and no dividend. Corporate events modestly lift the outlook due to the approved acquisition, tempered by merger-related litigation risk.

Positive Factors

Strong Balance Sheet

A strong balance sheet with low leverage and high equity provides financial stability, allowing Astria Therapeutics to fund its R&D efforts without immediate revenue pressure.

Scientific Expertise

The company's focus on scientific expertise ensures a robust pipeline of innovative drug candidates, positioning it well to address unmet medical needs in rare diseases.

Partnership Revenue Model

Astria's revenue model, based on partnerships, provides potential for upfront and milestone payments, offering financial support and market access for its drug candidates.

Negative Factors

Pre-Revenue Stage

Being in a pre-revenue stage with no current income stream increases financial risk, as the company relies heavily on external funding to sustain operations and development.

Increasing Net Losses

Rising net losses reflect the high costs associated with drug development, which could strain financial resources and delay profitability unless offset by successful product launches.

Negative Cash Flow

Negative cash flow indicates challenges in sustaining operations without external financing, highlighting the need for successful partnerships or product approvals to improve cash generation.

Astria Therapeutics Business Overview & Revenue Model

Company Description

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.

How the Company Makes Money

Astria Therapeutics makes money primarily through the development and commercialization of its proprietary drug candidates. The company generates revenue through partnerships and collaborations with larger pharmaceutical companies, which may include upfront payments, milestone payments, and potential royalties on sales of successfully developed drugs. Additionally, Astria Therapeutics may receive funding through grants and research collaborations. The company's revenue model typically involves significant investment in research and development, with potential returns materializing upon regulatory approval and market launch of its therapies.

Astria Therapeutics Financial Statement Overview

Summary

Financials reflect an R&D-stage biotech: minimal TTM revenue ($0.7M) with large and worsening losses (TTM net loss -$124.0M; EBIT -$136.5M) and accelerating cash burn (TTM operating cash flow -$119.7M; FCF -$120.3M). The main offset is very low leverage (debt-to-equity ~0.02), though equity and assets have declined versus 2024, underscoring reliance on future funding and pipeline progress.

Income Statement

ATXS remains a pre-revenue biotech with minimal revenue contribution in TTM (Trailing-Twelve-Months) ($0.7M) following $0 revenue across prior annual periods, while losses are sizable and persistent. Profitability is meaningfully negative in TTM (Trailing-Twelve-Months) (EBIT of -$136.5M; net loss of -$124.0M) versus the 2024 annual net loss of -$94.3M, indicating higher spending and a worsening earnings profile. The key strength is that losses are largely consistent with an R&D-stage model, but the weakness is the lack of commercial scale and no clear evidence of operating leverage yet.

Balance Sheet

The balance sheet is a relative bright spot: leverage is very low in TTM (Trailing-Twelve-Months) with debt of $4.5M against stockholders’ equity of $233.3M (debt-to-equity ~0.02), providing financial flexibility. However, equity and assets have declined from 2024 (equity: $319.3M; assets: $342.4M) to TTM (Trailing-Twelve-Months) (equity: $233.3M; assets: $271.9M), consistent with ongoing cash burn. Returns to shareholders remain negative (TTM return on equity about -39%), highlighting that the company is still consuming capital rather than generating it.

Cash Flow

Cash generation is weak, with operating cash flow deeply negative in TTM (Trailing-Twelve-Months) (-$119.7M) and free cash flow also negative (-$120.3M), reflecting heavy investment and operating outflows. Cash burn increased versus 2024 (operating cash flow of -$81.2M; free cash flow of -$81.5M), which raises financing dependence risk if the trend persists. A mitigating point is that free cash flow generally tracks net losses closely (TTM free cash flow to net income ~1.0), suggesting losses are largely cash-backed rather than driven by large non-cash distortions.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	706.00K	0.00	0.00	0.00	0.00	0.00
Gross Profit	706.00K	0.00	0.00	0.00	0.00	0.00
EBITDA	-134.05M	-111.56M	-83.03M	-53.50M	-30.36M	-37.41M
Net Income	-124.03M	-94.26M	-72.89M	-51.83M	-194.91M	-37.30M
Balance Sheet
Total Assets	271.87M	342.36M	254.67M	230.63M	127.51M	47.46M
Cash, Cash Equivalents and Short-Term Investments	227.72M	328.13M	246.53M	226.44M	125.51M	44.93M
Total Debt	4.46M	5.35M	329.00K	939.00K	365.00K	1.05M
Total Liabilities	38.61M	23.10M	11.55M	9.42M	5.20M	6.79M
Stockholders Equity	233.25M	319.26M	243.12M	221.22M	122.31M	40.67M
Cash Flow
Free Cash Flow	-120.32M	-81.54M	-68.47M	-43.62M	-30.17M	-32.52M
Operating Cash Flow	-119.73M	-81.21M	-68.44M	-43.53M	-30.15M	-32.48M
Investing Cash Flow	135.11M	-191.86M	135.05M	-167.13M	-12.55M	6.30M
Financing Cash Flow	3.00K	157.20M	88.40M	144.72M	104.28M	40.86M

Astria Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 12.58
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ATXS, the sentiment is Positive. The current price of 12.58 is below the 20-day moving average (MA) of 12.81, below the 50-day MA of 12.75, and above the 200-day MA of 8.28, indicating a neutral trend. The MACD of -0.05 indicates Positive momentum. The RSI at 46.09 is Neutral, neither overbought nor oversold. The STOCH value of 25.80 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ATXS.

Astria Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GLUE	75 Outperform	$1.74B	74.79	9.28%	―	1112.27%	―
AUTL	56 Neutral	$388.57M	-1.73	-60.52%	―	407.86%	30.35%
PRTC	55 Neutral	$443.88M	10.18	14.55%	―	1268.81%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ATXS	51 Neutral	$718.13M	-5.85	-43.15%	―	―	-2.74%
ADCT	48 Neutral	$447.20M	-2.49	―	―	6.35%	39.57%
FDMT	47 Neutral	$454.80M	-2.02	-45.38%	―	―	―

Astria Therapeutics Corporate Events

Astria Shareholders Approve Acquisition by BioCryst Pharmaceuticals

At a special meeting held on January 21, 2026, Astria Therapeutics stockholders approved the company’s acquisition by BioCryst Pharmaceuticals, with approximately 62.6% of outstanding shares represented and a strong majority voting in favor of the merger. Shareholders also backed, on a non-binding advisory basis, the merger-related compensation for named executive officers, and the parties indicated they expected the deal to close on or about January 23, 2026, signaling a major strategic shift for Astria as its pipeline of allergy and immunology therapies transitions under BioCryst’s ownership.

The most recent analyst rating on (ATXS) stock is a Sell with a $12.00 price target. To see the full list of analyst forecasts on Astria Therapeutics stock, see the ATXS Stock Forecast page.

Astria Faces Shareholder Lawsuits Over Planned BioCryst Merger

On October 14, 2025, Astria Therapeutics entered into a merger agreement with BioCryst Pharmaceuticals and a BioCryst subsidiary under which the subsidiary will merge into Astria, leaving Astria as a wholly owned unit of BioCryst, and BioCryst has filed the related registration statement while Astria has issued a definitive proxy statement for a stockholder vote on the deal. In mid-December 2025, two stockholder lawsuits were filed in New York state court alleging that Astria and its board negligently issued a false and misleading registration statement regarding the merger and seeking injunctive relief, damages, and fees, but the company has rejected the claims as without merit, arguing that any alleged misstatements are not material or actionable and pledging to vigorously defend the litigation while continuing to move the merger process forward.

The most recent analyst rating on (ATXS) stock is a Hold with a $13.00 price target. To see the full list of analyst forecasts on Astria Therapeutics stock, see the ATXS Stock Forecast page.